Dermatofibrosarcoma protuberans in children and adolescents: Primary and Relapsed disease-Experience of the Cooperative Weichteilsarkomstudiengruppe (CWS)

J Surg Oncol. 2020 Aug;122(2):263-272. doi: 10.1002/jso.25943. Epub 2020 May 19.

Abstract

Background: Dermatofibrosarcoma protuberans (DFSP) is a rare low-grade tumor. Little is known about best treatment of primary and relapsed disease (RD).

Methods: Treatment and outcome of 40 patients with DFSP prospectively registered within the CWS-96 and -2002P trials and the registry SoTiSaR (1996-2016) were analysed.

Results: Median age was 8 years (range, 0.64-17.77). Fluorescence in situ hybridization analysis to detect COL1A1-PDGFB fusion genes was positive in 86% (12/14) of evaluated patients. Primary resection was performed in all patients. Patients had IRS group I (n = 28), II (n = 9), and III (n = 2); not available (n = 1). To achieve complete remission (CR), a secondary resection was performed in 18 patients resulting in microscopically complete (R0, n = 34/40) and microscopically incomplete (R1, n = 5/40) resection. All patients achieved CR. The 5-year event-free survival (EFS) and overall survival was 86% (±12; CI, 95%) and 100% (±0; CI, 95%), respectively. R0 resection/IRS I was significantly favorable for the 5-year EFS. Local relapse occurred after a median time of 1.1 years (range, 0.04-5.1) in 15% (6/40) after CR. All patients with RD underwent resection and achieved CR. Three patients had fibrosarcomatous DFSP, two were alive after R0 resection.

Conclusion: Complete surgical resection is mandatory to prevent relapse of DFSP.

Keywords: CWS Group; children and adolescents; dermatofibrosarcoma protuberans; fibrosarcomatous transformation; surgery.

MeSH terms

  • Adolescent
  • Adult
  • Antineoplastic Agents / administration & dosage
  • Child
  • Dermatofibrosarcoma / drug therapy*
  • Dermatofibrosarcoma / genetics
  • Dermatofibrosarcoma / surgery*
  • Female
  • Humans
  • Imatinib Mesylate / administration & dosage
  • In Situ Hybridization, Fluorescence
  • Male
  • Oncogene Proteins, Fusion / genetics
  • Prognosis
  • Progression-Free Survival
  • Registries
  • Retrospective Studies
  • Skin Neoplasms / drug therapy*
  • Skin Neoplasms / genetics
  • Skin Neoplasms / surgery*
  • Young Adult

Substances

  • Antineoplastic Agents
  • COLIA1-PDGFB fusion protein, human
  • Oncogene Proteins, Fusion
  • Imatinib Mesylate